Yugang Guo

Yugang Guo

Auto-generated profile, based on publicly available information

Yugang Guo

Institute of Bioengineering, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2021 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
YGYugang Guo
Yugang Guo
YXYu-Qing Xie
Yu-Qing Xie
MGMin Gao
Min Gao
YZYang Zhao
Yang Zhao
FFFabien Franco
Fabien Franco
LTLi Tang
Li Tang

2 January 2024 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
YZYang Zhao
Yang Zhao
JCJiangqing Chen
Jiangqing Chen
MAMassimo Andreatta
Massimo Andreatta
BFBing Feng
Bing Feng
YXYu-Qing Xie
Yu-Qing Xie
LTLi Tang
Li Tang

6 December 2021 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
Kewen LeiKewen Lei
Kewen Lei
AKArmand Kurum
Armand Kurum
MKMurat Kaynak
Murat Kaynak
LBLucia Bonati
Lucia Bonati
YHYulong Han
Yulong Han
LTLi Tang
Li Tang

25 September 2024 in Nature
Verified
Journal Article
Open access
PDF file
BFBing Feng
Bing Feng
ZBZhiliang Bai
Zhiliang Bai
XZXiaolei Zhou
Xiaolei Zhou
YZYang Zhao
Yang Zhao
YXYu-Qing Xie
Yu-Qing Xie
LTLi Tang
Li Tang
Current cancer immunotherapy predominately focuses on eliciting type 1 immune responses fighting cancer; however, long-term complete remission remains uncommon1,2. A pivotal question arises as to whether type 2 immunity can be orchestrated alongside type 1-centric immunotherapy to achieve enduring response against cancer3,4. Here we show that an interleukin-4 fusion protein (Fc–IL-4), a typical type 2 cytokine, directly acts on CD8+ T cells and enriches functional terminally exhausted CD8+ T (CD8+ TTE) cells in the tumour. Consequently, Fc–IL-4 enhances antitumour efficacy of type 1 immunity-centric adoptive T cell transfer or immune checkpoint blockade therapies and induces durable remission across several syngeneic and xenograft tumour models. Mechanistically, we discovered that Fc–IL-4 signals through both signal transducer and activator of transcription 6 (STAT6) and mammalian target of rapamycin (mTOR) pathways, augmenting the glycolytic metabolism and the nicotinamide adenine dinucleotide (NAD) concentration of CD8+ TTE cells in a lactate dehydrogenase A-dependent manner. The metabolic modulation mediated by Fc–IL-4 is indispensable for reinvigorating intratumoural CD8+ TTE cells. These findings underscore Fc–IL-4 as a potent type 2 cytokine-based immunotherapy that synergizes effectively with type 1 immunity to elicit long-lasting responses against cancer. Our study not only sheds light on the synergy between these two types of immune responses, but also unveils an innovative strategy for advancing next-generation cancer immunotherapy by integrating type 2 immune factors.

10 September 2021 in Science Advances
Verified
Journal Article
Open access
YZYu Zhao
Yu Zhao
YXYu-Qing Xie
Yu-Qing Xie
SHSimon Van Herck
Simon Van Herck
SNSina Nassiri
Sina Nassiri
MGMin Gao
Min Gao
LTLi Tang
Li Tang
Chemically masked cytokines and antibodies turn active selectively in tumor as safer cancer immunotherapies.

26 February 2026 in Cell Reports
Verified
Journal Article
Open access
YWYi Wang
Yi Wang
CHChao Huang
Chao Huang
GCGuoxin Cai
Guoxin Cai
MAMassimo Andreatta
Massimo Andreatta
AKArmand Kurum
Armand Kurum
LTLi Tang
Li Tang
Natural killer (NK) cells, a type of potent cytotoxic lymphocyte, are particularly promising for the treatment of cancers that lose or downregulate major histocompatibility complex class I (MHC class I) expression to evade T cell-mediated immunotherapy. However, the hostile and immunosuppressive tumor microenvironment (TME) greatly hinders the function of tumor-infiltrating NK cells, thus limiting the therapeutic efficacy. Here, we show a fusion protein of interleukin 21 (IL-21-Fc) that safely and effectively reprograms NK cell metabolism and restores their effector function in vivo. IL-21-Fc synergizes with IL-15 superagonist (IL-15SA) or adoptive NK cell transfer to eradicate MHC class I-deficient tumors and confer durable protection across multiple murine models. Mechanistically, we uncover that IL-21-Fc enhances NK cell effector function by upregulating glycolysis in a lactate dehydrogenase A (LDHA)-dependent manner. This study reveals LDHA-dependent metabolic reprogramming as a key axis for NK cell rejuvenation and positions IL-21-Fc as a promising, clinically translatable strategy to overcome TME-mediated suppression in solid tumors.